Загрузка...
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
OBJECTIVE: Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, excoriations and limited therapies. Dupilumab, a monoclonal antibody against interleukin-4 receptor alpha, is a promising new treatment option for atopic dermatitis. We sought to systema...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752457/ https://ncbi.nlm.nih.gov/pubmed/29312544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22499 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|